Dominic R. Cundari - Feb 1, 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: Chief Commercial Officer
Signature: /s/ Amy Culbert, attorney-in-fact
Stock symbol: DMAC
Transactions as of: Feb 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/2/2022, 03:45 PM
Next filing: Jun 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						2.8K	Feb 1, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+125K		$0.00	125K	Feb 1, 2022	Common Shares	125K	$2.90	Direct	F1
transaction	DMAC	Stock Option (right to buy)	Award	$0	+40K		$0.00	40K	Feb 1, 2022	Common Shares	40K	$2.90	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option vests with respect to 31,250 common shares on February 1, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date.
F2	This option vests with respect to 10,000 common shares on May 1, 2022 and with respect to the remaining 75% of the common shares in three nearly equal installments on each of August 1, 2022, November 1, 2022 and February 1, 2023.